Literature DB >> 23432792

Renal tubular dysfunction in children with sickle cell haemoglobinopathy.

Mohamed Badr1, Mohamed A El Koumi, Yasser F Ali, Salah El-Morshedy, Nermin Abd Almonem, Tamer Hassan, Rehab Abd El Rahman, Mona Afify.   

Abstract

AIM: Children with sickle cell disease (SCD) are remarkably more prone than others to renal dysfunction. The kidneys, as one of the systemic long-term hazards in SCD, may be affected by both the haemodynamic changes of chronic anaemia as well as by the consequences of vaso-occlusion. The aim of this study was to evaluate the proximal tubular function in a group of Saudi children with established SCD.
METHODS: This study was conducted in Al-Khafji Joint Operations (KJO) Hospital, in Saudi Arabia during the period from June 2011 to August 2012. Thirty-four children: Group I (18 males and 16 females) with SCD (HBSS) and 27 children: Group II (17 males and 10 females) with sickle cell trait (HBAS) were evaluated for urinary excretion of retinol binding protein (RBP) and - Beta 2 microglobulin (β2 MG).
RESULTS: Group I patients showed a significantly impaired urinary concentrating ability compared to that of Group II (417 ± 94 mOsm/kg vs 581 ± 165 mOsm/kg). The urinary excretions of RBP and β2-microglobulin were significantly higher in Group I than in Group II. The values were 762.01 ± 124.20 μg/L and 841.84 ± 389.02 μg/L versus 198.12 ± 42.24 μg/L and 298.3 ± 38.11 μg/L, respectively.
CONCLUSION: Significant proximal tubular dysfunction was a feature in the SCD group, indicated by high urinary RBP and β2-microglobulin excretion. Assessing the urinary excretion of these low molecular weight proteins in children with sickle cell disease at different points of diagnosis may add key clinical information to the follow up of renal tubular function in patients with SCD.
© 2013 The Authors. Nephrology © 2013 Asian Pacific Society of Nephrology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23432792     DOI: 10.1111/nep.12040

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  4 in total

1.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

Review 2.  Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment.

Authors:  Essa Hariri; Anthony Mansour; Andrew El Alam; Yazan Daaboul; Serge Korjian; Sola Aoun Bahous
Journal:  Int Urol Nephrol       Date:  2018-01-30       Impact factor: 2.370

Review 3.  Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.

Authors:  Christos P Argyropoulos; Shan Shan Chen; Yue-Harn Ng; Maria-Eleni Roumelioti; Kamran Shaffi; Pooja P Singh; Antonios H Tzamaloukas
Journal:  Front Med (Lausanne)       Date:  2017-06-15

4.  Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia.

Authors:  Kenneth I Ataga; Vimal K Derebail; Melissa Caughey; Laila Elsherif; Jessica H Shen; Susan K Jones; Poulami Maitra; David M Pollock; Jianwen Cai; David R Archer; Alan L Hinderliter
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.